Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
6.83
+0.10 (1.49%)
At close: Aug 1, 2025, 4:00 PM
6.83
0.00 (0.00%)
After-hours: Aug 1, 2025, 6:04 PM EDT
Despegar.com Revenue
In the year 2024, Fulcrum Therapeutics had annual revenue of $80.00M with 2,752.05% growth.
Revenue (ttm)
$80.00M
Revenue Growth
+2,752.05%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
45
Market Cap
369.45M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 80.00M | 77.20M | 2,752.05% |
| Dec 31, 2023 | 2.81M | -3.54M | -55.77% |
| Dec 31, 2022 | 6.34M | -12.82M | -66.90% |
| Dec 31, 2021 | 19.16M | 10.34M | 117.19% |
| Dec 31, 2020 | 8.82M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 57.37B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
FULC News
- 3 days ago - Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 - GlobeNewsWire
- 3 days ago - Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - GlobeNewsWire
- 4 days ago - Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - GlobeNewsWire
- 21 days ago - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Fulcrum Therapeutics to Present at Upcoming Medical Meetings - GlobeNewsWire
- 2 months ago - Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Fulcrum Therapeutics to Participate in Upcoming May Conferences - GlobeNewsWire
- 3 months ago - Fulcrum Therapeutics, Inc. (FULC) Q1 2025 Earnings Call Transcript - Seeking Alpha